Increased risk of type 2 diabetes in antidepressant users: evidence from a 6-year longitudinal study in the E3N cohort

M Azevedo Da Silva, A Fournier, M-C Boutron-Ruault, B Balkau, F Bonnet, H Nabi, G Fagherazzi, M Azevedo Da Silva, A Fournier, M-C Boutron-Ruault, B Balkau, F Bonnet, H Nabi, G Fagherazzi

Abstract

Aim: To examine the association between antidepressant medication use and the risk of type 2 diabetes.

Methods: Data were obtained from the E3N study (Étude Épidémiologique de Femmes de la Mutuelle Générale de l'Éducation Nationale), a French cohort study initiated in 1990, with questionnaire-based follow-up every 2 or 3 years. Exposure to antidepressants was obtained from drug reimbursement files available from 2004 onwards, and individually matched with questionnaire data. Cases of type 2 diabetes were identified from drug reimbursements. Cox proportional-hazard regression models were used, with drug exposure considered as a time-varying parameter.

Results: Of the 63 999 women who were free of drug-treated type 2 diabetes at baseline in 2005, 1124 developed type 2 diabetes over the 6-year follow-up. Current use of antidepressants was associated with an increased risk of type 2 diabetes [hazard ratio 1.34 (95% CI 1.12, 1.61)] compared to non-users. When the different types of antidepressants were considered, women who currently used selective serotonin reuptake inhibitors, imipramine-type, 'other' or 'mixed' antidepressants had a 1.25-fold (95% CI 0.99, 1.57), 1.66-fold (95% CI 1.12, 2.46), 1.35-fold (95% CI 1.00, 1.84) and 1.82-fold (95% CI 0.85, 3.86) increase in risk of type 2 diabetes compared to non-users, respectively.

Conclusion: Our study suggests a positive association between antidepressant use and the risk of type 2 diabetes among women. If this association is confirmed, screening and surveillance of glucose levels should be considered in the context of antidepressant therapy. Further studies assessing the underlying mechanisms of this association are needed. (ClinicalTrials.gov identifier: NCT03285230).

© 2020 Diabetes UK.

References

    1. Fosse-Edorh S, Mandereau-Bruno L, Regnault N. The burden of diabetes-related complications in France in 2013. Summary and perspectives. Bull Epidémiol Hebd 2015;34-35: 619-625.
    1. da Rocha Fernandes J, Ogurtsova K, Linnenkamp U, Guariguata L, Seuring T, Zhang P et al. IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes. Diabetes Res Clin Pract 2016; 117: 48-54.
    1. WHO. Global report on diabetes. [cited 2018 Apr 6]. Available at . Last accessed 7 January 2020.
    1. Rubin RR, Ma Y, Marrero DG, Peyrot M, Barrett-Connor EL, Kahn SE et al. Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care 2008; 31: 420-426.
    1. Pan A, Sun Q, Okereke OI, Rexrode KM, Rubin RR, Lucas M et al. Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults. Diabetologia 2012; 55: 63-72.
    1. Kivimäki M, Hamer M, Batty GD, Geddes JR, Tabak AG, Pentti J et al. Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. Diabetes Care 2010; 33: 2611-2616.
    1. Bhattacharya R, Ajmera M, Bhattacharjee S, Sambamoorthi U. Use of antidepressants and statins and short-term risk of new-onset diabetes among high risk adults. Diabetes Res Clin Pract 2014; 105: 251-260.
    1. Chang KJ, Hong CH, Lee Y, Lee KS, Roh HW, Back JH et al. Effect of Psychotropic Drugs on Development of Diabetes Mellitus in Patients With Alzheimer’s Disease. Medicine (Baltimore) 2015; 94: e919.
    1. Bhattacharjee S, Bhattacharya R, Kelley GA, Sambamoorthi U. Antidepressant use and new-onset diabetes: a systematic review and meta-analysis. Diabetes Metab Res Rev 2013; 29: 273-284.
    1. Yoon JM, Cho E-G, Lee H-K, Park SM. Antidepressant use and diabetes mellitus risk: a meta-analysis. Korean J Fam Med 2013; 34: 228-240.
    1. Salvi V, Grua I, Cerveri G, Mencacci C, Barone-Adesi F. The risk of new-onset diabetes in antidepressant users - A systematic review and meta-analysis. PloS One 2017; 12: e0182088.
    1. Barnard K, Peveler RC, Holt RIG. Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review. Diabetes Care 2013; 36: 3337-3345.
    1. Kivimäki M, Batty GD, Jokela M, Ebmeier KP, Vahtera J, Virtanen M et al. Antidepressant medication use and risk of hyperglycemia and diabetes mellitus: a noncausal association? Biol Psychiatry 2011; 70: 978-984.
    1. Azevedo Da Silva M, Dugravot A, Balkau B, Roussel R, Fumeron F, Elbaz A et al. Antidepressant medication use and trajectories of fasting plasma glucose, glycated haemoglobin, β-cell function and insulin sensitivity: a 9-year longitudinal study of the D.E.S.I.R. cohort. Int J Epidemiol 2015; 44: 1927-1940.
    1. Clavel-Chapelon F, E3N Study Group. Cohort Profile: The French E3N Cohort Study. Int J Epidemiol 2015; 44: 801-809.
    1. Kengne AP, Beulens JWJ, Peelen LM, Moons KGM, van der Schouw YT, Schulze MB et al. Non-invasive risk scores for prediction of type 2 diabetes (EPIC-InterAct): a validation of existing models. Lancet Diabetes Endocrinol 2014; 2: 19-29.
    1. Mancini FR, Dow C, Affret A, Rajaobelina K, Dartois L, Balkau B et al. Micronutrient dietary patterns associated with type 2 diabetes mellitus among women of the E3N-EPIC (Etude Epidémiologique auprès de femmes de l’Education Nationale) cohort study. J Diabetes 2018; 10: 665-674.
    1. Thiébaut ACM, Bénichou J. Choice of time-scale in Cox’s model analysis of epidemiologic cohort data: a simulation study. Stat Med 2004; 23: 3803-3820.
    1. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982; 69: 239-241.
    1. Radloff LS. The CES-D Scale: A self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385-401.
    1. Fuhrer R, Rouillon F. La version française de l’échelle CES-D (Center for Epidemiologic Studies-Depression Scale). Description et traduction de l’échelle d’autoévaluation. [The French version of the CES-D (Center for Epidemiologic Studies-Depression Scale).]. Psychiatr Psychobiol 1989; 4: 163-166.
    1. Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009; 166: 591-598.
    1. Ma Y, Balasubramanian R, Pagoto SL, Schneider KL, Culver AL, Olendzki B et al. Elevated depressive symptoms, antidepressant use, and diabetes in a large multiethnic national sample of postmenopausal women. Diabetes Care 2011; 34: 2390-2392.
    1. Khoza S, Barner JC, Bohman TM, Rascati K, Lawson K, Wilson JP. Use of antidepressant agents and the risk of type 2 diabetes. Eur J Clin Pharmacol 2012; 68: 1295-1302.
    1. Kazes M, Danion JM, Grangé D, Pradignac A, Simon C, Burrus-Mehl F et al. Eating behaviour and depression before and after antidepressant treatment: a prospective, naturalistic study. J Affect Disord 1994; 30: 193-207.
    1. Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J Clin Psychopharmacol 1988; 8: 323-330.
    1. Dryden S, Brown M, King P, Williams G. Decreased plasma leptin levels in lean and obese Zucker rats after treatment with the serotonin reuptake inhibitor fluoxetine. Horm Metab Res 1999; 31: 363-366.
    1. Ahima RS. Revisiting leptin’s role in obesity and weight loss. J Clin Invest 2008; 118: 2380-2383.
    1. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-770.
    1. Salvi V, Barone-Adesi F, D’Ambrosio V, Albert U, Maina G. High H1-affinity antidepressants and risk of metabolic syndrome in bipolar disorder. Psychopharmacology (Berl) 2016; 233: 49-56.
    1. Fagherazzi G, El Fatouhi D, Fournier A, Gusto G, Mancini FR, Balkau B et al. Associations Between Migraine and Type 2 Diabetes in Women. JAMA Neurol 2019; 76: 257-263.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren